{"protocolSection": {"identificationModule": {"nctId": "NCT01115855", "orgStudyIdInfo": {"id": "A6141114"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure", "officialTitle": "The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure", "acronym": "J-EMPHASIS-HF"}, "statusModule": {"statusVerifiedDate": "2020-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-07"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-30", "studyFirstSubmitQcDate": "2010-04-30", "studyFirstPostDateStruct": {"date": "2010-05-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-05", "resultsFirstSubmitQcDate": "2016-09-05", "resultsFirstPostDateStruct": {"date": "2016-10-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-12-19", "lastUpdatePostDateStruct": {"date": "2020-12-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.", "detailedDescription": "The aim of this study was to show consistency with the EMPHASIS-HF trial (NCT00232180), which was defined as a HR of the primary endpoint of below 1."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Double-blind", "eplerenone", "Japanese"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 221, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Eplerenone arm", "type": "EXPERIMENTAL", "description": "Add on standard heart failure therapy", "interventionNames": ["Drug: Eplerenone"]}, {"label": "Placebo arm", "type": "PLACEBO_COMPARATOR", "description": "Add on standard heart failure therapy", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Eplerenone", "description": "Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily", "armGroupLabels": ["Eplerenone arm"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo once daily or every once daily", "armGroupLabels": ["Placebo arm"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF)", "description": "CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}], "secondaryOutcomes": [{"measure": "Number of Participants With First Occurrence of Cardiovascular (CV) Mortality, Hospitalization Due to Heart Failure (HF), or Addition/Increase of Heart Failure (HF) Medication", "description": "CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percentage (%) or more in dose of HF medication for \\>= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With With First Occurrence of All-Cause Mortality", "description": "All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Mortality during treatment, within 30 days of treatment discontinuation and after 30 days of discontinuation was reported. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With With First Occurrence of Cardiovascular Mortality", "description": "CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of All-cause Hospitalization", "description": "All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Hospitalization Due to Heart Failure (HF)", "description": "Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of All-cause Mortality or All-cause Hospitalization", "description": "All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization", "description": "HF mortality was defined as any death due to HF. Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization", "description": "CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Addition/Increase of Heart Failure (HF) Medication Due to Heart Failure (HF) Worsening", "description": "Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percent or more in dose of HF medication for \\>= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Fatal/Non-Fatal Stroke", "description": "Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Fatal/Non-Fatal Myocardial Infarction (MI)", "description": "Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of New Onset Atrial Fibrillation/Flutter", "description": "New onset of atrial fibrillation or flutter was defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of New Onset Diabetes Mellitus", "description": "New onset diabetes mellitus was defined as the diagnosis of diabetes mellitus in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Hospitalisation Due to Worsening Renal Function", "description": "Hospitalization due to worsening renal function (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Number of Participants With First Occurrence of Hospitalization for Hyperkalemia", "description": "Hospitalization due to hyperkalemia (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)"}, {"measure": "Change From Baseline in Plasma Concentration of Brain Natriuretic Peptide at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "timeFrame": "Baseline, Months 5,9,13,17,21,25,29,33,37,42,48, Final Visit (up to Month 48)"}, {"measure": "Change From Baseline in Plasma Concentration of Serum N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21 ,25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)"}, {"measure": "Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "LVEF was calculated based on end-diastolic volume measured by two-dimensional echocardiography.", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)"}, {"measure": "Change From Baseline in Urine Albumin-to-Creatinine Ratio at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)"}, {"measure": "Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).", "timeFrame": "Baseline, Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)"}, {"measure": "Change From Baseline in Specific Activity Scale (SAS) Score at Week 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "Specific activity scale was estimated by pre-specified questionnaire (for different activities) to assess the exercise capability of the participants. Answers provided by participants were transformed in terms of number of metabolic equivalents (METs).1 MET was defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml oxygen per kg body weight\\* minute. Scale ranged from 1 (less than (\\<) 2 METs) = lowest level of exercise tolerance to 6 (\\>=8METs) = highest level of tolerance and higher score indicated more tolerance.", "timeFrame": "Baseline, Week 4, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Japanese chronic systolic heart failure patients with LVEF =\\<30% by echocardiography and NYHA II or more\n* Patients who receive standard therapy (Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blocker or diuretic)\n\nExclusion Criteria:\n\n* Patients with a myocardial infarction, stroke, cardiac surgery or percutaneous coronary intervention within 30 days prior to randomization.\n* Patients with serum potassium \\>5.0 mmol/L or eGFR \\<30 ml/min/1.73 m2.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "55 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Chubu Rosai Hospital", "city": "Nagoya", "state": "Aichi", "zip": "455-8530", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Tosei General Hospital", "city": "Seto", "state": "Aichi", "zip": "489-8642", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "National Hospital Organization Chiba Medical Center", "city": "Chiba-shi", "state": "Chiba-ken", "zip": "260-8606", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Asahi General Hospital", "city": "Asahi", "state": "Chiba", "zip": "289-2511", "country": "Japan", "geoPoint": {"lat": 35.71667, "lon": 140.65}}, {"facility": "Nippon Medical School Chiba Hokusou Hospital", "city": "Inzai", "state": "Chiba", "zip": "270-1694", "country": "Japan", "geoPoint": {"lat": 35.83479, "lon": 140.16361}}, {"facility": "Ehime Prefectural Central Hospital", "city": "Matuyama-shi", "state": "Ehime", "zip": "790-0024", "country": "Japan"}, {"facility": "Kyushu University Hospital", "city": "Fukuoka-shi", "state": "Fukuoka-ken", "zip": "812-8582", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Aso Iizuka Hospital", "city": "Iizuka-shi", "state": "Fukuoka-ken", "zip": "820-8505", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"facility": "Kurume University Hospital", "city": "Kurume-shi", "state": "Fukuoka-ken", "zip": "830-0011", "country": "Japan", "geoPoint": {"lat": 33.31667, "lon": 130.51667}}, {"facility": "Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU Medical Clinic", "city": "Koriyama", "state": "Fukushima", "zip": "963-8052", "country": "Japan", "geoPoint": {"lat": 37.4, "lon": 140.38333}}, {"facility": "Ogaki Municipal Hospital", "city": "Ogaki", "state": "Gifu", "zip": "503-8502", "country": "Japan", "geoPoint": {"lat": 35.35, "lon": 136.61667}}, {"facility": "National Hospital Organization Hakodate National Hospital", "city": "Hakodate-shi", "state": "Hokkai-do", "zip": "041-8512", "country": "Japan", "geoPoint": {"lat": 41.77583, "lon": 140.73667}}, {"facility": "Hakodate City Hospital", "city": "Hakodate", "state": "Hokkaido", "zip": "041-8680", "country": "Japan", "geoPoint": {"lat": 41.77583, "lon": 140.73667}}, {"facility": "Teine Keijinkai Clinic", "city": "Sapporo", "state": "Hokkaido", "zip": "006-0811", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Hokkaido University Hospital", "city": "Sapporo", "state": "Hokkaido", "zip": "060-8648", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "National Hospital Organization Hokkaido Medical Center", "city": "Sapporo", "state": "Hokkaido", "zip": "063-0005", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Hyogo Brain and Heart Center", "city": "Himeji", "state": "Hyogo", "zip": "670-0981", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Japanease Red Cross Society Himeji Hospital", "city": "Himeji", "state": "Hyogo", "zip": "670-8540", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "The Hospital of Hyogo College of Medicine", "city": "Nishinomiya", "state": "Hyogo", "zip": "663-8501", "country": "Japan", "geoPoint": {"lat": 34.71562, "lon": 135.33199}}, {"facility": "Toride Kyodo General Hospital", "city": "Toride-shi", "state": "Ibaraki", "zip": "302-0022", "country": "Japan", "geoPoint": {"lat": 35.9, "lon": 140.08333}}, {"facility": "Mitoyo General Hospital", "city": "Kannonji", "state": "Kagawa", "zip": "769-1695", "country": "Japan", "geoPoint": {"lat": 38.97189, "lon": 139.93872}}, {"facility": "Fujisawa City Hospital", "city": "Fujisawa", "state": "Kanagawa", "zip": "251-8550", "country": "Japan", "geoPoint": {"lat": 35.34926, "lon": 139.47666}}, {"facility": "Kitasato University Hospital", "city": "Sagamihara", "state": "Kanagawa", "zip": "252-0375", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Mie University Hospital", "city": "Tsu", "state": "MIE", "zip": "514-8507", "country": "Japan", "geoPoint": {"lat": 34.73333, "lon": 136.51667}}, {"facility": "National Hospital Organization Sendai Medical Center", "city": "Sendai-shi", "state": "Miyagi-ken", "zip": "983-8520", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Nara Medical University Hospital", "city": "Kashihara", "state": "Nara", "zip": "634-8522", "country": "Japan", "geoPoint": {"lat": 34.50896, "lon": 135.7929}}, {"facility": "National Cerebral and Cardiovascular Center Hospital", "city": "Suita-shi", "state": "Osaka-fu", "zip": "565-8565", "country": "Japan", "geoPoint": {"lat": 34.76143, "lon": 135.51567}}, {"facility": "Kishiwada Tokushukai Hospital", "city": "Kishiwada", "state": "Osaka", "zip": "596-0042", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Sakai City Medical Center", "city": "Sakai-shi", "state": "Osaka", "zip": "593-8304", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 135.46667}}, {"facility": "Gokeikai Osaka Kaisei Hospital", "city": "Yodogawa-ku", "state": "Osaka", "zip": "532-0003", "country": "Japan"}, {"facility": "Shuwa General Hospital", "city": "Kasukabe-shi", "state": "Saitama", "zip": "344-0035", "country": "Japan", "geoPoint": {"lat": 35.98308, "lon": 139.74966}}, {"facility": "Saitama Medical Center Jichi Medical University", "city": "Saitama-shi", "state": "Saitama", "zip": "330-0834", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Kusatsu General Hospital", "city": "Kusatsu-shi", "state": "Shiga-ken", "zip": "525-8585", "country": "Japan", "geoPoint": {"lat": 35.01667, "lon": 135.96667}}, {"facility": "Hamamatsu Rosai Hospital", "city": "Hamamatsu-shi", "state": "Shizuoka", "zip": "430-8525", "country": "Japan", "geoPoint": {"lat": 34.7, "lon": 137.73333}}, {"facility": "Jichi Medical University Hospital", "city": "Shimotsuke-shi", "state": "Tochigi", "zip": "329-0498", "country": "Japan", "geoPoint": {"lat": 36.41323, "lon": 139.86622}}, {"facility": "Tokushima Red Cross Hospital", "city": "Komatsushima", "state": "Tokushima", "zip": "773-8502", "country": "Japan"}, {"facility": "Juntendo University Hospital", "city": "Bunkyo-ku", "state": "Tokyo", "zip": "113-8431", "country": "Japan", "geoPoint": {"lat": 35.37517, "lon": 139.92991}}, {"facility": "Mitsui Memorial Hospital", "city": "Chiyoda-Ku", "state": "Tokyo", "zip": "101-8643", "country": "Japan"}, {"facility": "Tokyo Women's Medical University Hospital", "city": "Shinjuku-ku", "state": "Tokyo", "zip": "162-8666", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Tottori University Hospital", "city": "Yonago-shi", "state": "Tottori", "zip": "683-8504", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 133.33333}}, {"facility": "Ube-kohsan Central Hospital Corp.", "city": "Ube-city", "state": "Yamaguchi", "zip": "755-0151", "country": "Japan", "geoPoint": {"lat": 33.94306, "lon": 131.25111}}, {"facility": "Yamaguchi University Hospital", "city": "Ube", "state": "Yamaguchi", "zip": "755-8505", "country": "Japan", "geoPoint": {"lat": 33.94306, "lon": 131.25111}}, {"facility": "University of Yamanashi Hospital", "city": "Chuo", "state": "Yamanashi", "zip": "409-3898", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Hamanomachi Hospital", "city": "Fukuoka", "zip": "810-8539", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Fukushima Medical University Hospital", "city": "Fukushima", "zip": "960-1295", "country": "Japan", "geoPoint": {"lat": 37.75, "lon": 140.46667}}, {"facility": "Gifu Prefectural General Medical Center", "city": "Gifu", "zip": "500-8727", "country": "Japan", "geoPoint": {"lat": 35.42291, "lon": 136.76039}}, {"facility": "Kumamoto University Hospital", "city": "Kumamoto", "zip": "860-8556", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "Saiseikai Kumamoto Hospital", "city": "Kumamoto", "zip": "861-4101", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "Japanese Red Cross Okayama Hospital", "city": "Okayama", "zip": "700-8607", "country": "Japan", "geoPoint": {"lat": 34.65, "lon": 133.93333}}, {"facility": "National Hospital Organization Osaka National Hospital", "city": "Osaka", "zip": "540-0006", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Osaka Police Hospital", "city": "Osaka", "zip": "543-0035", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Osaka General Medical Center", "city": "Osaka", "zip": "558-8558", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "National Hospital Organization Takasaki General Medical Center", "city": "Takasaki-shi", "zip": "370-0829", "country": "Japan", "geoPoint": {"lat": 36.33333, "lon": 139.01667}}, {"facility": "Toyama University Hospital", "city": "Toyama", "zip": "930-0152", "country": "Japan", "geoPoint": {"lat": 36.7, "lon": 137.21667}}]}, "referencesModule": {"references": [{"pmid": "28824029", "type": "DERIVED", "citation": "Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, Sunagawa K, Yasumura Y, Yano M, Yamamoto K, Yoshikawa T, Tsutamoto T, Zhang J, Okayama A, Ichikawa Y, Kanmuri K, Matsuzaki M; J-EMPHASIS-HF Study Group. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ J. 2017 Dec 25;82(1):148-158. doi: 10.1253/circj.CJ-17-0323. Epub 2017 Aug 19."}], "seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6141114&StudyName=Clinical%20Study%20Of%20Eplerenone%20In%20Japanese%20Patients%20With%20Chronic%20Heart%20Failure%20"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Eplerenone", "description": "Participants with estimated glomerular filtration rate (eGFR) greater than or equal to (\\>=) 50 milliliter per minute divided by 1.73 squared meter (mL/min/1.73m\\^2) received eplerenone 25 milligram (mg) tablet once daily up to Week 4 and participants with eGFR 30 to less than (\\<) 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. . From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "FG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "110"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "75"}, {"groupId": "FG001", "numSubjects": "74"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "36"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lab Abnormality", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set included all randomized participants.", "groups": [{"id": "BG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "BG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "221"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.0", "spread": "8.7"}, {"groupId": "BG001", "value": "68.4", "spread": "7.7"}, {"groupId": "BG002", "value": "68.7", "spread": "8.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "FEMALE", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "45"}]}, {"title": "MALE", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "176"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF)", "description": "CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline New York Heart Association (NYHA) cohort (II, III/IV) and baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "1.36"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Cardiovascular (CV) Mortality, Hospitalization Due to Heart Failure (HF), or Addition/Increase of Heart Failure (HF) Medication", "description": "CV mortality was defined as any death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percentage (%) or more in dose of HF medication for \\>= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.31"}]}, {"type": "SECONDARY", "title": "Number of Participants With With First Occurrence of All-Cause Mortality", "description": "All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Mortality during treatment, within 30 days of treatment discontinuation and after 30 days of discontinuation was reported. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "During treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Within 30 days of treatment discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "After 30 days of treatment discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "1.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "3.87"}]}, {"type": "SECONDARY", "title": "Number of Participants With With First Occurrence of Cardiovascular Mortality", "description": "CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "2.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.92", "ciUpperLimit": "6.24"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of All-cause Hospitalization", "description": "All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "0.97"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Hospitalization Due to Heart Failure (HF)", "description": "Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "1.25"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of All-cause Mortality or All-cause Hospitalization", "description": "All cause hospitalization included all hospitalizations as CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris and non-CV hospitalizations which was defined as any hospitalization due to non-CV events including renal dysfunction, hyperkalaemia, malignant tumor and pulmonary disease. All-cause mortality was defined as any CV mortality, Non-CV mortality, including malignant tumor, pulmonary disease and trauma.CV mortality was defined as death due to HF, myocardial infarction, cardiac arrhythmia, stroke or cerebral vascular accident, other CV cause (such as aneurysm or pulmonary embolism). Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "0.97"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Heart Failure (HF) Mortality or Heart Failure (HF) Hospitalization", "description": "HF mortality was defined as any death due to HF. Hospitalization due to HF was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to HF. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>=-50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.49", "ciUpperLimit": "1.33"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Cardiovascular (CV) Hospitalization", "description": "CV hospitalization, which was defined as any hospitalization due to CV events including HF, myocardial infarction, arrhythmia, angina pectoris. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "1.10"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Addition/Increase of Heart Failure (HF) Medication Due to Heart Failure (HF) Worsening", "description": "Addition/ increase of HF medications was defined as administration of new HF medication or increase of 50 percent or more in dose of HF medication for \\>= 3 days. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "1.28"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Fatal/Non-Fatal Stroke", "description": "Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.18", "ciUpperLimit": "3.53"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Fatal/Non-Fatal Myocardial Infarction (MI)", "description": "Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "1.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.07", "ciUpperLimit": "17.85"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of New Onset Atrial Fibrillation/Flutter", "description": "New onset of atrial fibrillation or flutter was defined as the diagnosis of atrial fibrillation or flutter in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "2.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.39", "ciUpperLimit": "11.56"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of New Onset Diabetes Mellitus", "description": "New onset diabetes mellitus was defined as the diagnosis of diabetes mellitus in a participant after randomization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "0.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.05", "ciUpperLimit": "5.66"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Hospitalisation Due to Worsening Renal Function", "description": "Hospitalization due to worsening renal function (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to worsening renal function as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cox Proportional Hazard Model with baseline NYHA cohort (II, III/IV) and baseline eGFR (30--\\<50 ml/min/1.73 m\\^2, \\>-=50 ml/min/1.73 m\\^2) covariates.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Hazard Ratio (HR)", "paramValue": "1.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.16", "ciUpperLimit": "8.04"}]}, {"type": "SECONDARY", "title": "Number of Participants With First Occurrence of Hospitalization for Hyperkalemia", "description": "Hospitalization due to hyperkalemia (as per physician's decision) was defined as an overnight stay, or longer, in a hospital environment (emergency room, observation unit or in-patient care, or similar facility including admission to a day care facility) due to hyperkalemia as the primary reason for hospitalization. Hazard ratio of Eplerenone versus placebo for first occurrence of the event was obtained from a Cox proportional hazards model.", "populationDescription": "Full analysis set included all randomized participants.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Randomization up to the date when the last enrolled participant had been followed up for 1 year (up to 1744 days)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Plasma Concentration of Brain Natriuretic Peptide at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picogram/milliliter (pg/ml)", "timeFrame": "Baseline, Months 5,9,13,17,21,25,29,33,37,42,48, Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Baseline (n=111,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "469.29", "spread": "375.43"}, {"groupId": "OG001", "value": "435.61", "spread": "391.49"}]}]}, {"title": "Change at Month 5 (n=105,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-169.75", "spread": "424.40"}, {"groupId": "OG001", "value": "-36.36", "spread": "413.73"}]}]}, {"title": "Change at Month 9 (n=99,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-208.54", "spread": "405.74"}, {"groupId": "OG001", "value": "-76.23", "spread": "442.47"}]}]}, {"title": "Change at Month 13 (n=95,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-258.66", "spread": "395.05"}, {"groupId": "OG001", "value": "-93.99", "spread": "409.87"}]}]}, {"title": "Change at Month 17 (n=81,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-242.92", "spread": "431.59"}, {"groupId": "OG001", "value": "-69.74", "spread": "535.05"}]}]}, {"title": "Change at Month 21 (n=72,73)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-241.33", "spread": "429.24"}, {"groupId": "OG001", "value": "-57.31", "spread": "515.76"}]}]}, {"title": "Change at Month 25 (n=63,63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-249.76", "spread": "473.68"}, {"groupId": "OG001", "value": "-83.99", "spread": "506.79"}]}]}, {"title": "Change at Month 29 (n=53,48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-269.07", "spread": "502.78"}, {"groupId": "OG001", "value": "-95.33", "spread": "350.51"}]}]}, {"title": "Change at Month 33 (n=45,40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-228.84", "spread": "575.05"}, {"groupId": "OG001", "value": "-43.98", "spread": "500.78"}]}]}, {"title": "Change at Month 37 (n=40,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-211.86", "spread": "597.30"}, {"groupId": "OG001", "value": "-73.73", "spread": "626.13"}]}]}, {"title": "Change at Month 42 (n=30,26)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-155.65", "spread": "320.44"}, {"groupId": "OG001", "value": "-22.31", "spread": "689.26"}]}]}, {"title": "Change at Month 48 (n=16,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-200.85", "spread": "357.51"}, {"groupId": "OG001", "value": "-122.33", "spread": "450.87"}]}]}, {"title": "Change at Final Visit (n=109,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-149.75", "spread": "473.95"}, {"groupId": "OG001", "value": "-57.45", "spread": "509.85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 5 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-102.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-195.92", "ciUpperLimit": "-9.94", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "47.13"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 9 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-95.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-184.51", "ciUpperLimit": "-7.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "44.54"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-125.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-195.50", "ciUpperLimit": "-54.68", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "35.15"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 17 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-31.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-232.77", "ciUpperLimit": "-31.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "51.12"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 21 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-132.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-240.94", "ciUpperLimit": "-23.84", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "52.77"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 25 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-117.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-221.49", "ciUpperLimit": "-12.87", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "51.76"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 29 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-101.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-267.36", "ciUpperLimit": "64.36", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "61.05"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 33 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-110.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-307.49", "ciUpperLimit": "85.93", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "92.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 37 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-119.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2137.82", "ciUpperLimit": "1898.59", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "158.84"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 42 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-144.60", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2692.95", "ciUpperLimit": "2403.76", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "200.56"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 48 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-77.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2131.88", "ciUpperLimit": "1977.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "966.09"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : ANCOVA with treatment effect and covariates of the NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-102.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-172.61", "ciUpperLimit": "-32.00", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "35.67"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Plasma Concentration of Serum N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21 ,25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Baseline (n=111,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2635.78", "spread": "2143.64"}, {"groupId": "OG001", "value": "2354.31", "spread": "1874.30"}]}]}, {"title": "Change at Month 5 (n=105,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-770.51", "spread": "2172.88"}, {"groupId": "OG001", "value": "-205.18", "spread": "1801.42"}]}]}, {"title": "Change at Month 9 (n=99,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-884.76", "spread": "2265.57"}, {"groupId": "OG001", "value": "-425.47", "spread": "1883.54"}]}]}, {"title": "Change at Month 13 (n=95,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1066.86", "spread": "2088.51"}, {"groupId": "OG001", "value": "-452.02", "spread": "1878.98"}]}]}, {"title": "Change at Month 17 (n=81,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1126.96", "spread": "2384.14"}, {"groupId": "OG001", "value": "-109.59", "spread": "3380.42"}]}]}, {"title": "Change at Month 21 (n=72,73)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-957.86", "spread": "2601.47"}, {"groupId": "OG001", "value": "-250.85", "spread": "2508.01"}]}]}, {"title": "Change at Month 25 (n=63,63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-453.57", "spread": "4894.51"}, {"groupId": "OG001", "value": "-128.02", "spread": "2627.01"}]}]}, {"title": "Change at Month 29 (n=53,48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1013.83", "spread": "3167.91"}, {"groupId": "OG001", "value": "-187.08", "spread": "2524.52"}]}]}, {"title": "Change at Month 33 (n=45,40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-168.36", "spread": "5404.82"}, {"groupId": "OG001", "value": "434.35", "spread": "5134.98"}]}]}, {"title": "Change at Month 37 (n=40,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.64", "spread": "5188.24"}, {"groupId": "OG001", "value": "171.21", "spread": "5081.43"}]}]}, {"title": "Change at Month 42 (n=30,26)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-246.77", "spread": "4753.87"}, {"groupId": "OG001", "value": "928.35", "spread": "6494.32"}]}]}, {"title": "Change at Month 48 (n=16,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-970.71", "spread": "4833.60"}, {"groupId": "OG001", "value": "-450.69", "spread": "1487.78"}]}]}, {"title": "Change at Final Visit (n=109,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-177.00", "spread": "3780.44"}, {"groupId": "OG001", "value": "296.35", "spread": "3823.59"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 5 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-364.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1863.06", "ciUpperLimit": "1133.76", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "763.83"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 9 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-247.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1642.43", "ciUpperLimit": "1148.14", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "711.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-370.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1742.51", "ciUpperLimit": "1002.22", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "699.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 17 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-664.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-141189.93", "ciUpperLimit": "139861.75", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11059.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 21 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-414.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39445.52", "ciUpperLimit": "38615.54", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3071.77"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 25 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "23.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21649.89", "ciUpperLimit": "21697.60", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10794.85"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 29 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-245.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-85358.69", "ciUpperLimit": "84868.22", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6698.57"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 33 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "170.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21375.69", "ciUpperLimit": "21716.66", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10730.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 37 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-58.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30160.25", "ciUpperLimit": "30042.70", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "12765.30"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 42 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-212.25", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22723.82", "ciUpperLimit": "22299.33", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11073.11"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 48 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-80.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-146026.28", "ciUpperLimit": "145865.96", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "11486.21"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : ANCOVA with treatment effect and covariates of the NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-187.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-662.67", "ciUpperLimit": "287.23", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "240.96"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "LVEF was calculated based on end-diastolic volume measured by two-dimensional echocardiography.", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of LVEF", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Baseline (n=111,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.64", "spread": "4.95"}, {"groupId": "OG001", "value": "26.64", "spread": "3.97"}]}]}, {"title": "Change at Month 5 (n=105,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.98", "spread": "8.87"}, {"groupId": "OG001", "value": "4.01", "spread": "7.59"}]}]}, {"title": "Change at Month 9 (n=99,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.89", "spread": "10.64"}, {"groupId": "OG001", "value": "31.37", "spread": "9.19"}]}]}, {"title": "Change at Month 13 (n=94,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.62", "spread": "9.70"}, {"groupId": "OG001", "value": "4.86", "spread": "10.13"}]}]}, {"title": "Change at Month 17 (n=81,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.36", "spread": "11.45"}, {"groupId": "OG001", "value": "5.50", "spread": "10.74"}]}]}, {"title": "Change at Month 21 (n=72,73)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.73", "spread": "12.04"}, {"groupId": "OG001", "value": "6.37", "spread": "11.88"}]}]}, {"title": "Change at Month 25 (n=63,64)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.18", "spread": "12.18"}, {"groupId": "OG001", "value": "6.60", "spread": "10.94"}]}]}, {"title": "Change at Month 29 (n=53,48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.95", "spread": "12.28"}, {"groupId": "OG001", "value": "6.45", "spread": "12.83"}]}]}, {"title": "Change at Month 33 (n=45,39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.67", "spread": "13.94"}, {"groupId": "OG001", "value": "5.20", "spread": "10.19"}]}]}, {"title": "Change at Month 37 (n=40,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.34", "spread": "14.59"}, {"groupId": "OG001", "value": "7.18", "spread": "10.49"}]}]}, {"title": "Change at Month 42 (n=30,26)", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.15", "spread": "14.38"}, {"groupId": "OG001", "value": "5.13", "spread": "10.36"}]}]}, {"title": "Change at Month 48 (n=16,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.18", "spread": "16.02"}, {"groupId": "OG001", "value": "8.41", "spread": "11.51"}]}]}, {"title": "Change at Final Visit (n=109,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.50", "spread": "12.03"}, {"groupId": "OG001", "value": "5.99", "spread": "11.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 5 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "1.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "3.96", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.14"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 9 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "2.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.07", "ciUpperLimit": "5.42", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.36"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "3.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "6.60", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.39"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 17 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "4.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.81", "ciUpperLimit": "7.90", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.54"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 21 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "5.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.36", "ciUpperLimit": "8.94", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.67"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 25 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "3.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "6.75", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 29 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "3.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "7.25", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.85"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 33 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "4.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.86", "ciUpperLimit": "8.44", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.92"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 37 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "3.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "7.68", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.94"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 42 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "4.67", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.08", "ciUpperLimit": "9.25", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.31"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 48 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "4.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.82", "ciUpperLimit": "10.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.98"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 : ANCOVA with treatment effect and covariates of the NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "3.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "5.80", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.33"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Urine Albumin-to-Creatinine Ratio at Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "microgram per gram creatinine (mg/gCr)", "timeFrame": "Baseline, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Baseline (n=111,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "169.82", "spread": "787.32"}, {"groupId": "OG001", "value": "154.93", "spread": "366.44"}]}]}, {"title": "Change at Month 5 (n=104,103)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.14", "spread": "359.53"}, {"groupId": "OG001", "value": "46.23", "spread": "377.56"}]}]}, {"title": "Change at Month 9 (n=98,101)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.10", "spread": "249.68"}, {"groupId": "OG001", "value": "23.79", "spread": "362.35"}]}]}, {"title": "Change at Month 13 (n=94,98)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-41.56", "spread": "322.12"}, {"groupId": "OG001", "value": "-19.04", "spread": "253.57"}]}]}, {"title": "Change at Month 17 (n=80,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.66", "spread": "247.48"}, {"groupId": "OG001", "value": "79.28", "spread": "530.74"}]}]}, {"title": "Change at Month 21 (n=72,73)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-63.65", "spread": "498.00"}, {"groupId": "OG001", "value": "28.84", "spread": "431.48"}]}]}, {"title": "Change at Month 25 (n=62,63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.17", "spread": "489.08"}, {"groupId": "OG001", "value": "30.08", "spread": "350.86"}]}]}, {"title": "Change at Month 29 (n=50,47)", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.51", "spread": "454.75"}, {"groupId": "OG001", "value": "-4.58", "spread": "504.53"}]}]}, {"title": "Change at Month 33 (n=43,39)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-47.07", "spread": "506.66"}, {"groupId": "OG001", "value": "-3.38", "spread": "417.43"}]}]}, {"title": "Change at Month 37 (n=39,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-80.21", "spread": "743.85"}, {"groupId": "OG001", "value": "34.20", "spread": "393.95"}]}]}, {"title": "Change at Month 42 (n=27,25)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-162.18", "spread": "921.61"}, {"groupId": "OG001", "value": "-29.95", "spread": "187.19"}]}]}, {"title": "Change at Month 48 (n=16,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-303.19", "spread": "1211.28"}, {"groupId": "OG001", "value": "-41.03", "spread": "113.70"}]}]}, {"title": "Change at Final Visit (n=109,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.30", "spread": "597.07"}, {"groupId": "OG001", "value": "-31.56", "spread": "271.71"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 5: Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-61.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-186.44", "ciUpperLimit": "63.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "59.75"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 9 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-24.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-131.27", "ciUpperLimit": "81.39", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "54.20"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-12.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-97.28", "ciUpperLimit": "72.13", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "43.18"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 17 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-78.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-221.25", "ciUpperLimit": "64.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "72.78"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 21 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-79.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-211.88", "ciUpperLimit": "52.63", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "67.42"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 25 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "19.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-230.01", "ciUpperLimit": "268.71", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "88.95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 29: Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-21.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-194.21", "ciUpperLimit": "152.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "88.27"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 33: Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-40.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-197.55", "ciUpperLimit": "115.97", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "79.91"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 37 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-44.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-247.11", "ciUpperLimit": "158.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "103.29"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 42 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-27.69", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-238.31", "ciUpperLimit": "182.93", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "107.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 48: Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-31.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-221.17", "ciUpperLimit": "158.24", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "96.48"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13 :ANCOVA with treatment effect and covariates of the NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-2.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-58.91", "ciUpperLimit": "54.83", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "28.85"}]}, {"type": "SECONDARY", "title": "Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline, Weeks 1, 4, Months 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48 and Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Week 1 (n=111, 110) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Week 1 (n=111, 110) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "107"}]}]}, {"title": "Week 1 (n=111, 110) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Week 4 (n=111, 108) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Week 4 (n=111, 108) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "92"}]}]}, {"title": "Week 4 (n=111, 108) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Month 2 (n=109, 109) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Month 2 (n=109, 109) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "95"}]}]}, {"title": "Month 2 (n=109, 109) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Month 3 (n=106, 107) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Month 3 (n=106, 107) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "91"}]}]}, {"title": "Month 3 (n=106, 107) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Month 4 (n=106, 106) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Month 4 (n=106, 106) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "86"}]}]}, {"title": "Month 4 (n=106, 106) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Month 5 (n=104, 106) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Month 5 (n=104, 106) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "83"}]}]}, {"title": "Month 5 (n=104, 106) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Month 9 (n=99, 105) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Month 9 (n=99, 105) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "81"}]}]}, {"title": "Month 9 (n=99, 105) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Month 13 (n=94, 102) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Month 13 (n=94, 102) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "82"}]}]}, {"title": "Month 13 (n=94, 102) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Month 17 (n=81, 82) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Month 17 (n=81, 82) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "61"}]}]}, {"title": "Month 17 (n=81, 82) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Month 21 (n=72, 73) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Month 21 (n=72, 73) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "51"}]}]}, {"title": "Month 21 (n=72, 73) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Month 25 (n=63, 64) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Month 25 (n=63, 64) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "48"}]}]}, {"title": "Month 25 (n=63, 64) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Month 29 (n=53, 48) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "Month 29 (n=53, 48) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "Month 29 (n=53, 48) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Month 33 (n=46, 39) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Month 33 (n=46, 39) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "27"}]}]}, {"title": "Month 33 (n=46, 39) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Month 37 (n=40, 33) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Month 37 (n=40, 33) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "Month 37 (n=40, 33) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Month 42 (n=30, 26) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Month 42 (n=30, 26) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Month 42 (n=30, 26) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Month 48 (n=16, 16) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Month 48 (n=16, 16) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Month 48 (n=16, 16) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Final Visit (n=111, 110) : Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "26"}]}]}, {"title": "Final Visit (n=111, 110) : Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "80"}]}]}, {"title": "Final Visit (n=111, 110) : Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Specific Activity Scale (SAS) Score at Week 4, Months 2, 3, 4, 5, 9, 13, 17 21, 25, 29, 33, 37, 42, 48 and Final Visit", "description": "Specific activity scale was estimated by pre-specified questionnaire (for different activities) to assess the exercise capability of the participants. Answers provided by participants were transformed in terms of number of metabolic equivalents (METs).1 MET was defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml oxygen per kg body weight\\* minute. Scale ranged from 1 (less than (\\<) 2 METs) = lowest level of exercise tolerance to 6 (\\>=8METs) = highest level of tolerance and higher score indicated more tolerance.", "populationDescription": "Full analysis set included all randomized participants. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "metabolic equivalents (METs)", "timeFrame": "Baseline, Week 4, Months 5, 9, 13, 17, 21, 25, 29, 33, 37, 42, 48, Final Visit (up to Month 48)", "groups": [{"id": "OG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48."}, {"id": "OG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Baseline (n=111,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.85", "spread": "1.51"}, {"groupId": "OG001", "value": "4.89", "spread": "1.54"}]}]}, {"title": "Change at Week 4 (n= 111,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.79"}, {"groupId": "OG001", "value": "0.27", "spread": "1.08"}]}]}, {"title": "Change at Month 5 (n=104,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "1.15"}, {"groupId": "OG001", "value": "0.33", "spread": "1.19"}]}]}, {"title": "Change at Month 9 (n=99,104)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.41", "spread": "1.16"}, {"groupId": "OG001", "value": "0.37", "spread": "1.39"}]}]}, {"title": "Change at Month 13 (n=94,102)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.52", "spread": "1.18"}, {"groupId": "OG001", "value": "0.44", "spread": "1.45"}]}]}, {"title": "Change at Month 17 (n=81,82)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "1.38"}, {"groupId": "OG001", "value": "0.47", "spread": "1.81"}]}]}, {"title": "Change at Month 21 (n=72,73)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.34", "spread": "1.33"}, {"groupId": "OG001", "value": "0.59", "spread": "1.64"}]}]}, {"title": "Change at Month 25 (n=63,63)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.48", "spread": "1.08"}, {"groupId": "OG001", "value": "0.63", "spread": "1.72"}]}]}, {"title": "Change at Month 29 (n=53,48)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.42", "spread": "1.14"}, {"groupId": "OG001", "value": "0.65", "spread": "1.56"}]}]}, {"title": "Change at Month 33 (n=46,40)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "spread": "1.28"}, {"groupId": "OG001", "value": "0.51", "spread": "1.80"}]}]}, {"title": "Change at Month 37 (n=40,33)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.53", "spread": "1.47"}, {"groupId": "OG001", "value": "0.68", "spread": "1.39"}]}]}, {"title": "Change at Month 42 (n=30,26)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.39", "spread": "1.70"}, {"groupId": "OG001", "value": "0.47", "spread": "1.83"}]}]}, {"title": "Change at Month 48 (n=16,16)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.13", "spread": "1.57"}, {"groupId": "OG001", "value": "0.64", "spread": "1.59"}]}]}, {"title": "Change at Final Visit (n=111,110)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "1.56"}, {"groupId": "OG001", "value": "0.25", "spread": "1.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 5 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "0.37", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.15"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 9 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.34", "ciUpperLimit": "0.30", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.16"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 13: Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "0.39", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.17"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 17 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.41", "ciUpperLimit": "0.45", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.22"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 21 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.56", "ciUpperLimit": "0.24", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.20"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 25 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "0.25", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.20"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 29 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.49", "ciUpperLimit": "0.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.20"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 33 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "0.44", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 37 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "0.54", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 42 :Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.20", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "0.83", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Month 48 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "0.89", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline at Week 4 : Mixed effect model of repeated measurements with covariates of the treatment, Week, interaction between treatment and week, baseline NYHA cohort (II, III/IV), baseline eGFR (30-\\<50 ml/min/1.73 m\\^2, \\>=50 ml/min/1.73 m\\^2) and baseline value.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "paramType": "Least Square Mean Difference", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "0.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.12"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "The same event may appear as both an adverse event and an serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non serious event during the study.", "eventGroups": [{"id": "EG000", "title": "Eplerenone", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet once daily up to Week 4 and participants with eGFR 30 to \\< 50 mL/min/1.73m\\^2 received eplerenone 25 mg tablet every other day up to Week 4. From Week 4 onward, the dose of eplerenone was limited to 50 mg once daily for participants with eGFR \\>=50 mL/min/1.73 m\\^2 and 25 mg once daily for participants with eGFR 30 to \\<50 mL/min/1.73 m\\^2 up to Month 48.", "seriousNumAffected": 52, "seriousNumAtRisk": 111, "otherNumAffected": 89, "otherNumAtRisk": 111}, {"id": "EG001", "title": "Placebo", "description": "Participants with eGFR \\>=50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet orally once daily from up to Week 4 and participants with eGFR 30 to \\<50 mL/min/1.73m\\^2 received placebo matched with eplerenone tablet every other day up to Week 4. From Week 4 onward, all participants received placebo matched with eplerenone tablet once daily up to Month 48.", "seriousNumAffected": 65, "seriousNumAtRisk": 110, "otherNumAffected": 87, "otherNumAtRisk": 110}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Bone marrow failure", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Disseminated intravascular coagulation", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Haemorrhagic diathesis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 110}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 110}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Cardiac sarcoidosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Congestive cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Intracardiac thrombus", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Protein-losing gastroenteropathy", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Multi-organ failure", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Device related infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Disseminated tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Endocarditis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Peritonitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Pneumonia staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Muscle injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Postoperative ileus", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Spinal cord injury cervical", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Arthritis reactive", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Muscle haemorrhage", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Colon adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Metastases to bone", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Oesophageal carcinoma recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Prostate cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Thyroid cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Cervical myelopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Spondylitic myelopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Organising pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Extremity necrosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Haemorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 110}]}, {"term": "Peripheral artery aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 32, "numAtRisk": 110}]}, {"term": "Chronic gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 110}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 110}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 110}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 110}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 37, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 40, "numAtRisk": 110}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 110}]}, {"term": "Blood pressure decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 110}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 110}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 110}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 110}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 110}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 110}]}, {"term": "Atrophic vulvovaginitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "As the event is gender specific, only female participants were evaluated.", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 110}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 110}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077545", "term": "Eplerenone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M1823", "name": "Eplerenone", "asFound": "Salvage", "relevance": "HIGH"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}